Swedbank AB Sells 1,375 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Swedbank AB reduced its stake in IQVIA Holdings Inc. by 1.6% during the first quarter, now owning 86,882 shares worth approximately $15.3 million.
• Several institutional investors have increased their positions in IQVIA, with Brighton Jones LLC topping the list with a 244.4% increase in the fourth quarter.
• IQVIA's stock has been subject to various analyst upgrades, with UBS raising its price target from $185 to $225, and an overall average analyst rating of "Moderate Buy".

Swedbank AB lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 86,882 shares of the medical research company's stock after selling 1,375 shares during the quarter. Swedbank AB owned about 0.05% of IQVIA worth $15,317,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of IQV. American National Bank & Trust bought a new stake in shares of IQVIA during the first quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd raised its position in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA in the first quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. increased its holdings in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Stock Up 0.5%

IQVIA stock traded up $1.00 during midday trading on Tuesday, reaching $186.97. The stock had a trading volume of 1,005,530 shares, compared to its average volume of 1,136,706. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $248.03. The company has a market capitalization of $31.78 billion, a P/E ratio of 27.06, a PEG ratio of 2.04 and a beta of 1.32. The company has a fifty day moving average price of $183.32 and a two-hundred day moving average price of $167.24. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the subject of several recent research reports. JPMorgan Chase & Co. reduced their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Mizuho boosted their price target on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Evercore ISI raised their price objective on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. UBS Group raised their target price on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Citigroup reissued a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Eighteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $229.64.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.